(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 11.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.
Moderna's revenue in 2026 is $2,232,000,000.On average, 27 Wall Street analysts forecast MRNA's revenue for 2026 to be $800,892,999,600, with the lowest MRNA revenue forecast at $592,270,140,192, and the highest MRNA revenue forecast at $960,290,240,496. On average, 23 Wall Street analysts forecast MRNA's revenue for 2027 to be $917,315,494,176, with the lowest MRNA revenue forecast at $616,492,269,936, and the highest MRNA revenue forecast at $1,266,973,657,416.
In 2028, MRNA is forecast to generate $1,284,554,235,456 in revenue, with the lowest revenue forecast at $388,226,044,665 and the highest revenue forecast at $3,024,640,781,904.